CoQ10 and Heart Health: What the Research Shows
Last reviewed: 21 марта 2026 г. 11:53
Coenzyme Q10 (CoQ10), also known as ubiquinone, is a naturally occurring compound found in virtually every cell in the body, with particularly high concentrations in the heart, liver, kidneys, and muscles. It plays a dual role in cellular physiology: serving as an essential electron carrier in the mitochondrial electron transport chain (critical for ATP energy production) and functioning as a lipid-soluble antioxidant that protects cell membranes from oxidative damage. Endogenous CoQ10 production declines with age, and certain medications — most notably statins (HMG-CoA reductase inhibitors) — further reduce CoQ10 levels by inhibiting the mevalonate pathway, which is shared by both cholesterol and CoQ10 biosynthesis.
The most compelling cardiovascular evidence for CoQ10 comes from the Q-SYMBIO trial (2014), a randomized, double-blind, placebo-controlled study of 420 patients with moderate-to-severe heart failure. Patients receiving 100 mg of CoQ10 three times daily for two years showed a significant 43% relative risk reduction in major adverse cardiovascular events (cardiovascular death, heart failure hospitalization, cardiac transplant, or mechanical circulatory support) compared to placebo. The absolute risk reduction was 14 percentage points (26% vs. 15%). While these results were striking, the trial was relatively small by cardiology standards, and larger confirmatory trials are needed before CoQ10 can be considered a standard heart failure therapy. The KiSel-10 trial also showed that combined CoQ10 and selenium supplementation reduced cardiovascular mortality in elderly Swedish participants over a 5-year follow-up.
CoQ10 supplementation for statin-associated muscle symptoms (SAMS) remains one of its most popular uses, but the evidence is decidedly mixed. Several small randomized controlled trials have reported improvements in muscle pain and weakness with CoQ10 supplementation (100-300 mg daily), while others, including a well-designed 2015 trial published in Atherosclerosis, found no benefit compared to placebo. A 2018 meta-analysis concluded that CoQ10 may reduce statin-related muscle symptoms, but the evidence quality was low and effect sizes were small. The substantial placebo response rate in SAMS trials (up to 40%) complicates interpretation. Nevertheless, given CoQ10's favorable safety profile, many clinicians consider a trial of supplementation reasonable for patients experiencing SAMS.
Regarding blood pressure, meta-analyses of randomized controlled trials have shown that CoQ10 supplementation may reduce systolic blood pressure by approximately 11 mmHg and diastolic by 7 mmHg, though study quality has been variable and more rigorous trials are needed. CoQ10 is available in two forms: ubiquinone (oxidized) and ubiquinol (reduced). Ubiquinol is generally better absorbed, particularly in older adults, though both forms are ultimately interconverted in the body. Typical dosages in cardiovascular trials range from 100 to 300 mg daily, often divided into two or three doses taken with fatty foods to enhance absorption. CoQ10 is generally well tolerated, with mild gastrointestinal symptoms being the most common side effect. It may interact with warfarin (potentially reducing its anticoagulant effect) and may enhance the blood pressure-lowering effects of antihypertensive medications. Consult your healthcare provider before starting CoQ10, particularly if you take blood thinners or blood pressure medications.
The most compelling cardiovascular evidence for CoQ10 comes from the Q-SYMBIO trial (2014), a randomized, double-blind, placebo-controlled study of 420 patients with moderate-to-severe heart failure. Patients receiving 100 mg of CoQ10 three times daily for two years showed a significant 43% relative risk reduction in major adverse cardiovascular events (cardiovascular death, heart failure hospitalization, cardiac transplant, or mechanical circulatory support) compared to placebo. The absolute risk reduction was 14 percentage points (26% vs. 15%). While these results were striking, the trial was relatively small by cardiology standards, and larger confirmatory trials are needed before CoQ10 can be considered a standard heart failure therapy. The KiSel-10 trial also showed that combined CoQ10 and selenium supplementation reduced cardiovascular mortality in elderly Swedish participants over a 5-year follow-up.
CoQ10 supplementation for statin-associated muscle symptoms (SAMS) remains one of its most popular uses, but the evidence is decidedly mixed. Several small randomized controlled trials have reported improvements in muscle pain and weakness with CoQ10 supplementation (100-300 mg daily), while others, including a well-designed 2015 trial published in Atherosclerosis, found no benefit compared to placebo. A 2018 meta-analysis concluded that CoQ10 may reduce statin-related muscle symptoms, but the evidence quality was low and effect sizes were small. The substantial placebo response rate in SAMS trials (up to 40%) complicates interpretation. Nevertheless, given CoQ10's favorable safety profile, many clinicians consider a trial of supplementation reasonable for patients experiencing SAMS.
Regarding blood pressure, meta-analyses of randomized controlled trials have shown that CoQ10 supplementation may reduce systolic blood pressure by approximately 11 mmHg and diastolic by 7 mmHg, though study quality has been variable and more rigorous trials are needed. CoQ10 is available in two forms: ubiquinone (oxidized) and ubiquinol (reduced). Ubiquinol is generally better absorbed, particularly in older adults, though both forms are ultimately interconverted in the body. Typical dosages in cardiovascular trials range from 100 to 300 mg daily, often divided into two or three doses taken with fatty foods to enhance absorption. CoQ10 is generally well tolerated, with mild gastrointestinal symptoms being the most common side effect. It may interact with warfarin (potentially reducing its anticoagulant effect) and may enhance the blood pressure-lowering effects of antihypertensive medications. Consult your healthcare provider before starting CoQ10, particularly if you take blood thinners or blood pressure medications.